BrainQ
BrainQ is a medical technology company that develops AI-powered electromagnetic stimulation therapy for stroke disability recovery. The company investigational therapy uses tailored, low-intensity, low-frequency electromagnetic stimulation to enhance the brain natural recovery process after stroke, designed for safe use in both clinical and home settings. BrainQ AI algorithms analyze patient data to personalize…
Funding snapshot
About
BrainQ is a medical technology company that develops AI-powered electromagnetic stimulation therapy for stroke disability recovery. The company investigational therapy uses tailored, low-intensity, low-frequency electromagnetic stimulation to enhance the brain natural recovery process after stroke, designed for safe use in both clinical and home settings. BrainQ AI algorithms analyze patient data to personalize treatment parameters, optimizing the electromagnetic stimulation patterns for each individual recovery trajectory. The technology aims to improve motor function recovery in stroke survivors by modulating neural network activity in affected brain regions, addressing the significant unmet need for effective post-stroke rehabilitation therapies. Founded in 2011 and headquartered in Jerusalem, Israel, BrainQ has raised $48.8 million through Series B funding from investors including Hanaco Ventures, Peregrine Ventures, EIC Fund, Dexcel, and OurCrowd.
Business model
Brain Computer Interface > Applications > Healthcare > Therapeutics,
Wearable Technology > Health and Wellness Devices > Neural,
Disease Self Management > Neurological Disorders > Therapy,
Neurology > Medical Devices > Therapeutic Devices > Stroke Rehabilitation
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.